{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:30:26Z","timestamp":1783510226082,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["23K06270"],"award-info":[{"award-number":["23K06270"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11010-024-05157-z","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T20:18:24Z","timestamp":1732565904000},"page":"2985-2999","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oxaliplatin and 5-fluorouracil promote epithelial-mesenchymal transition via activation of KRAS\/ERK\/NF-\u03baB pathway in KRAS-mutated colon cancer cells"],"prefix":"10.1007","volume":"480","author":[{"given":"Tadafumi","family":"Hoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Tsubaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik-hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koudai","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Imano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"5157_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"5157_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.clcc.2020.01.003","volume":"19","author":"E Maiello","year":"2020","unstructured":"Maiello E, Di Maggio G, Cordio S, Cinieri S, Giuliani F, Pisconti S, Rinaldi A, Febbraro A, Latiano TP, Aieta M, Rossi A, Rizzi D, Di Maio M, Colucci G, Bordonaro R (2020) Bevacizumab in combination with either FOLFOX-4 or XELOX-2 in first-line treatment of patients with metastatic colorectal cancer: a multicenter randomized phase ii trial of the gruppo oncologico dell\u2019italia meridionale (GOIM 2802). Clin Colorectal Cancer 19:109\u2013115. https:\/\/doi.org\/10.1016\/j.clcc.2020.01.003","journal-title":"Clin Colorectal Cancer"},{"key":"5157_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/COC.0b013e3182a2d7b8","volume":"38","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Coinu A, Ghilardi M, Cabiddu M, Zaniboni A, Barni S (2015) Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials. Am J Clin Oncol 38:227\u2013233. https:\/\/doi.org\/10.1097\/COC.0b013e3182a2d7b8","journal-title":"Am J Clin Oncol"},{"key":"5157_CR4","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.mod.2003.06.005","volume":"120","author":"D Shook","year":"2003","unstructured":"Shook D, Keller R (2003) Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 120:1351\u20131383. https:\/\/doi.org\/10.1016\/j.mod.2003.06.005","journal-title":"Mech Dev"},{"key":"5157_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3892\/or.2022.8320","volume":"47","author":"T Takeda","year":"2022","unstructured":"Takeda T, Tsubaki M, Matsuda T, Kimura A, Jinushi M, Obana T, Takegami M, Nishida S (2022) EGFR inhibition reverses epithelial-mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells. Oncol Rep 47:109. https:\/\/doi.org\/10.3892\/or.2022.8320","journal-title":"Oncol Rep"},{"key":"5157_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1756-9966-32-62","volume":"32","author":"M Tsubaki","year":"2013","unstructured":"Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D, Mukai J, Sakaguchi K, Satou T, Nishida S (2013) Activation of NF-\u03baB by the RANKL\/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res 32:62. https:\/\/doi.org\/10.1186\/1756-9966-32-62","journal-title":"J Exp Clin Cancer Res"},{"key":"5157_CR7","doi-asserted-by":"publisher","first-page":"153303382210812","DOI":"10.1177\/15330338221081219","volume":"21","author":"Q Ni","year":"2022","unstructured":"Ni Q, Li M, Yu S (2022) Research progress of epithelial-mesenchymal transition treatment and drug resistance in colorectal cancer. Technol Cancer Res Treat 21:15330338221081220. https:\/\/doi.org\/10.1177\/15330338221081219","journal-title":"Technol Cancer Res Treat"},{"key":"5157_CR8","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S1470-2045(21)00343-0","volume":"22","author":"N Zhang","year":"2021","unstructured":"Zhang N, Ng AS, Cai S, Li Q, Yang L, Kerr D (2021) Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer. Lancet Oncol 22:e358\u2013e368. https:\/\/doi.org\/10.1016\/S1470-2045(21)00343-0","journal-title":"Lancet Oncol"},{"key":"5157_CR9","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1158\/1078-0432.CCR-08-2372","volume":"15","author":"QQ Li","year":"2009","unstructured":"Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP, Xu ZD (2009) Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15:2657\u20132665. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2372","journal-title":"Clin Cancer Res"},{"key":"5157_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3892\/or.2013.2876","volume":"31","author":"J Hara","year":"2014","unstructured":"Hara J, Miyata H, Yamasaki M, Sugimura K, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y (2014) Mesenchymal phenotype after chemotherapy is associated with chemoresistance and poor clinical outcome in esophageal cancer. Oncol Rep 31:589\u2013596. https:\/\/doi.org\/10.3892\/or.2013.2876","journal-title":"Oncol Rep"},{"key":"5157_CR11","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.3390\/cancers11121866","volume":"11","author":"M Tsubaki","year":"2019","unstructured":"Tsubaki M, Takeda T, Noguchi M, Jinushi M, Seki S, Morii Y, Shimomura K, Imano M, Satou T, Nishida S (2019) Overactivation of Akt contributes to MEK inhibitor primary and acquired resistance in colorectal cancer cells. Cancers 11:1866. https:\/\/doi.org\/10.3390\/cancers11121866","journal-title":"Cancers"},{"key":"5157_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41374-018-0114-8","volume":"99","author":"M Tsubaki","year":"2019","unstructured":"Tsubaki M, Takeda T, Tomonari Y, Koumoto YI, Imano M, Satou T, Nishida S (2019) Overexpression of HIF-1\u03b1 contributes to melphalan resistance in multiple myeloma cells by activation of ERK1\/2, Akt, and NF-\u03baB. Lab Invest 99:72\u201384. https:\/\/doi.org\/10.1038\/s41374-018-0114-8","journal-title":"Lab Invest"},{"key":"5157_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1755-8794-2-18","volume":"2","author":"H Mizuno","year":"2009","unstructured":"Mizuno H, Kitada K, Nakai K, Sarai A (2009) PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2:18. https:\/\/doi.org\/10.1186\/1755-8794-2-18","journal-title":"BMC Med Genomics"},{"key":"5157_CR14","first-page":"1205","volume":"6","author":"MA Graham","year":"2000","unstructured":"Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205\u20131218","journal-title":"Clin Cancer Res"},{"key":"5157_CR15","first-page":"2727","volume":"17","author":"JM Joulia","year":"1997","unstructured":"Joulia JM, Pinguet F, Ychou M, Duffour J, Topart D, Grosse PY, Astre C, Bressolle F (1997) Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). Anticancer Res 17:2727\u20132730","journal-title":"Anticancer Res"},{"key":"5157_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/jmcb\/mjy075","volume":"11","author":"M Nakayama","year":"2019","unstructured":"Nakayama M, Oshima M (2019) Mutant p53 in colon cancer. J Mol Cell Biol 11:267\u2013276. https:\/\/doi.org\/10.1093\/jmcb\/mjy075","journal-title":"J Mol Cell Biol"},{"key":"5157_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jtho.2018.11.021","volume":"14","author":"CA Lin","year":"2019","unstructured":"Lin CA, Yu SL, Chen HY, Chen HW, Lin SU, Chang CC, Yu CJ, Yang PC, Ho CC (2019) EGFR-mutant SCLC exhibits heterogeneous phenotypes and resistance to common antineoplastic drugs. J Thorac Oncol 14:513\u2013526. https:\/\/doi.org\/10.1016\/j.jtho.2018.11.021","journal-title":"J Thorac Oncol"},{"key":"5157_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejca.2017.06.033","volume":"83","author":"A Najem","year":"2017","unstructured":"Najem A, Krayem M, Sal\u00e8s F, Hussein N, Badran B, Robert C, Awada A, Journe F, Ghanem GE (2017) P53 and MITF\/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. Eur J Cancer 83:154\u2013165. https:\/\/doi.org\/10.1016\/j.ejca.2017.06.033","journal-title":"Eur J Cancer"},{"key":"5157_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s10637-018-0563-3","volume":"36","author":"S Liu","year":"2018","unstructured":"Liu S, Tang Y, Yan M, Jiang W (2018) PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation. Invest New Drugs 36:763\u2013772. https:\/\/doi.org\/10.1007\/s10637-018-0563-3","journal-title":"Invest New Drugs"},{"key":"5157_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1940-6207.CAPR-17-0230","volume":"11","author":"PFS Rice","year":"2018","unstructured":"Rice PFS, Ehrichs KG, Jones MS, Chen H, Hsu CH, Abril ER, Nagle RB, Besselsen DG, Barton JK, Ignatenko NA (2018) Does mutated K-RAS oncogene attenuate the effect of sulindac in colon cancer chemoprevention? Cancer Prev Res 11:16\u201326. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-17-0230","journal-title":"Cancer Prev Res"},{"key":"5157_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.bbrc.2006.11.091","volume":"352","author":"K Akagi","year":"2007","unstructured":"Akagi K, Uchibori R, Yamaguchi K, Kurosawa K, Tanaka Y, Kozu T (2007) Characterization of a novel oncogenic K-ras mutation in colon cancer. Biochem Biophys Res Commun 352:728\u2013732. https:\/\/doi.org\/10.1016\/j.bbrc.2006.11.091","journal-title":"Biochem Biophys Res Commun"},{"key":"5157_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.891665","volume":"13","author":"R Zhang","year":"2022","unstructured":"Zhang R, Li S, Lan J, Li C, Du X, Dong W, Yu Q, Wang D (2022) CNTN-1 Upregulation induced by low-dose cisplatin promotes malignant progression of lung adenocarcinoma cells via activation of epithelial-mesenchymal transition. Front Genet 13:891665. https:\/\/doi.org\/10.3389\/fgene.2022.891665","journal-title":"Front Genet"},{"key":"5157_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2008.02.007","volume":"62","author":"W Zhuo","year":"2008","unstructured":"Zhuo W, Wang Y, Zhuo X, Zhang Y, Ao X, Chen Z (2008) Knockdown of snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK\/mitochondrial pathway. Lung Cancer 62:8\u201314. https:\/\/doi.org\/10.1016\/j.lungcan.2008.02.007","journal-title":"Lung Cancer"},{"key":"5157_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111500","volume":"383","author":"CE Wu","year":"2019","unstructured":"Wu CE, Zhuang YW, Zhou JY, Liu SL, Wang RP, Shu P (2019) Cinnamaldehyde enhances apoptotic effect of oxaliplatin and reverses epithelial-mesenchymal transition and stemnness in hypoxic colorectal cancer cells. Exp Cell Res 383:111500. https:\/\/doi.org\/10.1016\/j.yexcr.2019.111500","journal-title":"Exp Cell Res"},{"key":"5157_CR25","doi-asserted-by":"publisher","first-page":"8836","DOI":"10.1111\/jcmm.16842","volume":"25","author":"B Zhang","year":"2021","unstructured":"Zhang B, Chan SH, Liu XQ, Shi YY, Dong ZX, Shao XR, Zheng LY, Mai ZY, Fang TL, Deng LZ, Zhou DS, Chen SN, Li M, Zhang XD (2021) Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer. J Cell Mol Med 25:8836\u20138849. https:\/\/doi.org\/10.1111\/jcmm.16842","journal-title":"J Cell Mol Med"},{"key":"5157_CR26","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1158\/1535-7163.MCT-14-0207","volume":"13","author":"VJ Findlay","year":"2014","unstructured":"Findlay VJ, Wang C, Nogueira LM, Hurst K, Quirk D, Ethier SP, Staveley O\u2019Carroll KF, Watson DK, Camp ER (2014) SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. Mol Cancer Ther 13:2713\u20132726. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0207","journal-title":"Mol Cancer Ther"},{"key":"5157_CR27","doi-asserted-by":"publisher","unstructured":"Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP (2021) Dynamic EMT: a multi-tool for tumor progression. EMBO J 40:e108647. https:\/\/doi.org\/10.15252\/embj.2021108647.","DOI":"10.15252\/embj.2021108647"},{"key":"5157_CR28","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2147\/OTT.S241367","volume":"13","author":"Y Chen","year":"2020","unstructured":"Chen Y, Deng G, Fu Y, Han Y, Guo C, Yin L, Cai C, Shen H, Wu S, Zeng S (2020) FOXC2 promotes oxaliplatin resistance by inducing epithelial-mesenchymal transition via MAPK\/ERK signaling in colorectal cancer. Onco Targets Ther 13:1625\u20131635. https:\/\/doi.org\/10.2147\/OTT.S241367","journal-title":"Onco Targets Ther"},{"key":"5157_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2017.09.041","volume":"411","author":"J Ma","year":"2017","unstructured":"Ma J, Zeng S, Zhang Y, Deng G, Qu Y, Guo C, Yin L, Han Y, Cai C, Li Y, Wang G, Bonkovsky HL, Shen H (2017) BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1\/ERK\/ELK1 signaling in hepatocellular carcinoma. Cancer Lett 411:117\u2013129. https:\/\/doi.org\/10.1016\/j.canlet.2017.09.041","journal-title":"Cancer Lett"},{"key":"5157_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bcp.2015.08.105","volume":"98","author":"C Buhrmann","year":"2015","unstructured":"Buhrmann C, Shayan P, Kraehe P, Popper B, Goel A, Shakibaei M (2015) Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem Pharmacol 98:51\u201368. https:\/\/doi.org\/10.1016\/j.bcp.2015.08.105","journal-title":"Biochem Pharmacol"},{"key":"5157_CR31","doi-asserted-by":"publisher","first-page":"706","DOI":"10.5483\/BMBRep.2019.52.12.234","volume":"52","author":"Y Jin","year":"2019","unstructured":"Jin Y, Huynh DTN, Kang KW, Myung CS, Heo KS (2019) Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT. BMB Rep 52:706\u2013711. https:\/\/doi.org\/10.5483\/BMBRep.2019.52.12.234","journal-title":"BMB Rep"},{"key":"5157_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.canlet.2016.06.014","volume":"380","author":"YX Lu","year":"2016","unstructured":"Lu YX, Ju HQ, Wang F, Chen LZ, Wu QN, Sheng H, Mo HY, Pan ZZ, Xie D, Kang TB, Chen G, Yun JP, Zeng ZL, Xu RH (2016) Inhibition of the NF-\u03baB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Lett 380:87\u201397. https:\/\/doi.org\/10.1016\/j.canlet.2016.06.014","journal-title":"Cancer Lett"},{"key":"5157_CR33","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.bbrc.2019.04.053","volume":"513","author":"Z Hu","year":"2019","unstructured":"Hu Z, Zhen L, Li Q, Han Q, Hua Q (2019) Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation. Biochem Biophys Res Commun 513:862\u2013868. https:\/\/doi.org\/10.1016\/j.bbrc.2019.04.053","journal-title":"Biochem Biophys Res Commun"},{"key":"5157_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.22034\/APJCP.2018.19.1.49","volume":"19","author":"E Meiyanto","year":"2018","unstructured":"Meiyanto E, Septisetyani EP, Larasati YA, Kawaichi M (2018) Curcumin analog pentagamavunon-1 (PGV-1) sensitizes widr cells to 5-fluorouracil through inhibition of NF-\u03baB activation. Asian Pac J Cancer Prev 19:49\u201356. https:\/\/doi.org\/10.22034\/APJCP.2018.19.1.49","journal-title":"Asian Pac J Cancer Prev"},{"key":"5157_CR35","doi-asserted-by":"publisher","first-page":"84974","DOI":"10.18632\/oncotarget.17761","volume":"8","author":"Z Lu","year":"2017","unstructured":"Lu Z, Lai ZQ, Leung AWN, Leung PS, Li ZS, Lin ZX (2017) Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies. Oncotarget 8:84974\u201384985. https:\/\/doi.org\/10.18632\/oncotarget.17761","journal-title":"Oncotarget"},{"key":"5157_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov R, Tsai CJ, Jang H (2021) Anticancer drug resistance: an update and perspective. Drug Resist Updat 59:100796. https:\/\/doi.org\/10.1016\/j.drup.2021.100796","journal-title":"Drug Resist Updat"},{"key":"5157_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12094-020-02402-x","volume":"23","author":"P Garc\u00eda-Alfonso","year":"2021","unstructured":"Garc\u00eda-Alfonso P, Garc\u00eda-Gonz\u00e1lez G, Gallego I, Peligros MI, Ortega L, Torres P\u00e9rez-Solero G, Sandoval C, Mu\u00f1oz Martin A, Blanco Codesido M, Calvo Ferr\u00e1ndiz A, Martin M (2021) Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study. Clin Transl Oncol 23:122\u2013129. https:\/\/doi.org\/10.1007\/s12094-020-02402-x","journal-title":"Clin Transl Oncol"},{"key":"5157_CR38","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3892\/or.2012.1669","volume":"27","author":"G Lin","year":"2012","unstructured":"Lin G, Tang Z, Ye YB, Chen Q (2012) NF-\u03baB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-I\u03baB\u03b1 pathway. Oncol Rep 27:1527\u20131534. https:\/\/doi.org\/10.3892\/or.2012.1669","journal-title":"Oncol Rep"},{"key":"5157_CR39","doi-asserted-by":"publisher","first-page":"806","DOI":"10.21873\/invivo.12767","volume":"36","author":"J Yu","year":"2022","unstructured":"Yu J, Zhang J, Peng T, Fei Z, Jin L, Yang M (2022) Predictive value of circulating tumor cells in prognosis of stage III\/IV colorectal cancer after oxaliplatin-based first-line chemotherapy. In Vivo 36:806\u2013813. https:\/\/doi.org\/10.21873\/invivo.12767","journal-title":"In Vivo"},{"key":"5157_CR40","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.athoracsur.2011.07.032","volume":"92","author":"Y Shintani","year":"2011","unstructured":"Shintani Y, Okimura A, Sato K, Nakagiri T, Kadota Y, Inoue M, Sawabata N, Minami M, Ikeda N, Kawahara K, Matsumoto T, Matsuura N, Ohta M, Okumura M (2011) Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg 92:1794\u20131804. https:\/\/doi.org\/10.1016\/j.athoracsur.2011.07.032","journal-title":"Ann Thorac Surg"},{"key":"5157_CR41","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1158\/1541-7786.MCR-19-0077","volume":"17","author":"C Yoon","year":"2019","unstructured":"Yoon C, Till J, Cho SJ, Chang KK, Lin JX, Huang CM, Ryeom S, Yoon SS (2019) KRAS activation in gastric adenocarcinoma stimulates epithelial-to-mesenchymal transition to cancer stem-like cells and promotes metastasis. Mol Cancer Res 17:1945\u20131957. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0077","journal-title":"Mol Cancer Res"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05157-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-024-05157-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05157-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:34:13Z","timestamp":1746185653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-024-05157-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["5157"],"URL":"https:\/\/doi.org\/10.1007\/s11010-024-05157-z","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}